STAT
Top-dose patients cut A1c by 2.2 points and lost 20.9% of body weight, versus 1.8 points and 9.4% on Ozempic, per Lilly's on-treatment analysis.
Recap by typeshit. Full story at STAT.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
The analysis argues retatrutide is still unapproved, so the year-end price rides on Mounjaro and Zepbound, which made up about 65% of last quarter's revenue.
New coverage looks at whether organized follow-up help can limit the weight that tends to come back once people come off GLP-1 drugs.
Loading…